Reston, VA—A new article in The Journal of Nuclear Medicine explores the potential for using ChatGPT, an artificial intelligence chatbot, in the field of nuclear medicine and molecular imaging. In the article, Irène Buvat, PhD, and Wolfgang Weber, MD, PhD, report on discussions they held with ChatGPT regarding several nuclear medicine and molecular imaging topics and provide their commentary on the pros and cons of using the chatbot.
Developed by OpenAI, ChatGPT is a natural language processing chatbot that can intelligently respond to questions. In conversations with users, the chatbot always “pays attention” and remembers the thread of the dialogue. It is available in more than 90 languages and can be instructed to adopt a specific style, for example, Shakesperean or journalistic language.
Credit: The Journal of Nuclear Medicine
Reston, VA—A new article in The Journal of Nuclear Medicine explores the potential for using ChatGPT, an artificial intelligence chatbot, in the field of nuclear medicine and molecular imaging. In the article, Irène Buvat, PhD, and Wolfgang Weber, MD, PhD, report on discussions they held with ChatGPT regarding several nuclear medicine and molecular imaging topics and provide their commentary on the pros and cons of using the chatbot.
Developed by OpenAI, ChatGPT is a natural language processing chatbot that can intelligently respond to questions. In conversations with users, the chatbot always “pays attention” and remembers the thread of the dialogue. It is available in more than 90 languages and can be instructed to adopt a specific style, for example, Shakesperean or journalistic language.
Buvat and Weber challenged ChatGPT with questions relevant to nuclear medicine and molecular imaging to illustrate the role it could play in the field. ChatGPT received no special preparation for the interview and responded entirely with information from its extensive dataset. The responses of ChatGPT illustrate the strengths and weaknesses of current artificial intelligence bots.
According to Buvat and Weber, artificial intelligence bots such as ChatGPT “should not be feared but rather considered promising allies who will help us cope with ever-increasing workloads, freeing up time to devote to patients and colleagues and to expend more energy on tasks that require unique and advanced expertise.”
The complete discussion with ChatGPT can be viewed HERE.
The authors of “Nuclear Medicine from a Novel Perspective: Buvat and Weber Talk with OpenAI’s ChatGPT” include Irène Buvat, Inserm Laboratory of Translational Imaging in Oncology, Institut Curie, Orsay, France, and Wolfgang Weber, University Hospital, Technische Universität, München, Munich, Germany.
Visit the JNM website for the latest research, and follow our new Twitter and Facebook pages @JournalofNucMed or follow us on LinkedIn.
###
Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or [email protected].
About JNM and the Society of Nuclear Medicine and Molecular Imaging
The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed 15 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.
JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org.
Journal
Journal of Nuclear Medicine
DOI
10.2967/jnumed.123.265636
Article Title
Nuclear Medicine from a Novel Perspective: Buvat and Weber Talk with OpenAI’s ChatGPT
Article Publication Date
23-Mar-2023